KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Assets (2019 - 2025)

Aurinia Pharmaceuticals' Assets history spans 6 years, with the latest figure at $751.6 million for Q4 2025.

  • For Q4 2025, Assets rose 36.49% year-over-year to $751.6 million; the TTM value through Dec 2025 reached $751.6 million, up 36.49%, while the annual FY2025 figure was $751.6 million, 36.49% up from the prior year.
  • Assets reached $751.6 million in Q4 2025 per AUPH's latest filing, up from $527.5 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $751.6 million in Q4 2025 to a low of $360.1 million in Q3 2021.
  • Average Assets over 5 years is $509.3 million, with a median of $511.8 million recorded in 2022.
  • Peak YoY movement for Assets: decreased 13.34% in 2022, then skyrocketed 36.49% in 2025.
  • A 5-year view of Assets shows it stood at $543.4 million in 2021, then fell by 13.34% to $470.9 million in 2022, then increased by 16.4% to $548.1 million in 2023, then grew by 0.47% to $550.6 million in 2024, then soared by 36.49% to $751.6 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Assets are $751.6 million (Q4 2025), $527.5 million (Q3 2025), and $502.6 million (Q2 2025).